Grass Pollen Allergy Treatment Market size was valued at 26,206.6 million in 2021 and is expected to reach 40,192.3 million by 2028, at a CAGR of 6.3% during the forecast period 2022 to 2028. Pollens are the tiny particles released by plants, trees, and grasses as a part of reproductive cycle in summer and spring seasons. Pollens inhaled by animals and humans can cause inflammation and irritation. Hay fever and allergic rhinitis are the commonly caused allergies due to grass pollen. Symptoms associated with grass pollen Allergy Treatment include running or blocked nose, frequent sneezing, itchy throat and nose among others. Pollens are microscopic particles emitted by trees, plants, and grasses as part of their reproductive cycle throughout the spring and summer. Pollen is easily swallowed by humans and animals because to its small particles, which can cause considerable irritation and inflammation in some people. Allergic rhinitis, sometimes known as hay fever, is one of the most prevalent allergies induced by grass pollen. According to a study published in 2010 by the American College of Allergy, Asthma & Immunology, around 16.9 million adults and 6.7 million children were diagnosed with hay fever, and the prevalence of the disease is increasing by about 30% in adults and 40% in children. Hay fever symptoms affect 500 million people in the United States and around the world.
In February 2018, ASIT Biotech raised € 13.9 Mn in funding for the Phase III clinical development of GP-ASIT+ used for grass pollen rhinitis